Dr Sanjiv Agarwala reviews data for first-line immunotherapy with nivolumab plus relatlimab demonstrating significantly improved progression-free survival over monotherapy, and a high pathologic complete response rate with this combination in the neoadjuvant setting, in patients with advanced melanoma. He also reviews data from the CheckMate-067 study showing durable 6.5-year overall survival with first-line nivolumab plus ipilimumab in patients with advanced melanoma.
Related Items
Conference Correspondent published on December 16, 2021 in Dual IO 2021 Year in Review
Conference Correspondent published on December 16, 2021 in Dual IO 2021 Year in Review